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Poster Session II 147potentially prevent the occurrence of GVHD if it were determined
that these cells underwent sufficient homeostatic proliferation to
generate the Treg:effector T cell ratios required to accomplish
this effect. While several studies have focused on the proliferation
of transferred CD41CD251 T cells, it is well known that CD25
is also present on activated T cells, and hence is not a definitive
marker for identifying Treg. In contrast, the transcription factor,
FoxP3, has been determined to be a more definitive marker. With
this in mind, we injected unseparated CD41 T cells from C57BL/
6 (B6) GFP1FoxP3 knock-in mice into lethally irradiated B6 recip-
ients to study the proliferation and homing potential of Treg in the
context of other T cells. On days 2 and 7 post-transplant, GFP1
cells were found in the spleen of recipient mice at double the num-
ber of those found in the mesenteric lymph nodes. Furthermore, in
contrast to previously published results in which onlyCD41CD251
Tcells were injected and proliferation was reported, our experimen-
tal design should help to elucidate the fate of FoxP31 Treg under
conditions that more closely represent BMT;whereTreg constitute
part of the transferred T cell population.406
EFFECT OF IL-7 ON HUMAN NK CELLS
Michaud, A., Dardari, R., Charrier, E., Cordero, P., Duval, M. Hoˆpital
Ste-Justine, Montreal, QC, Canada.
Background: NK cells are first immune cells to reappear after
HSCT and their activation may play a role in transplantation out-
come. IL-7 is currently under clinical investigation as a therapeutic
agent after HSCT. We demonstrated that human NK cells express
IL-7 receptor, with a higher expression by CD56bright NK cells.We
thus investigated the effect of IL-7 on NK cells.Methods: Activa-
tion markers were studied by flow cytometry, as well as inhibitory
receptors expression. Proliferation assays were performed by
CFSE staining. Cytotoxicity was studied by 51Cr release assay.
Results: IL-7 induced the expression of CD25 and CD69 and en-
hanced NKG2D expression. The expression pattern of inhibitory
receptors was altered by IL-7: fewer cells expressed KIR, whereas
more cells expressed NKG2A. IL-7 induced the proliferation of
CD56bright NK cells, but not the proliferation of CD56dimNK cells.
Cytotoxicity was increased in 4 out of 7 donors. Conclusion: The
effect of IL-7 on NK cells differs from one donor to another and
from a NK cells subset to another. This must be taken into account
in the interpretation of the results of clinical trials of IL-7 after
HSCT.407
PLASMATIC TNF-a, IL-2, IFN-g AND IL-10 ARE IMPORTANT CYTOKINES
TO CONTROL CML AFTER ALLOGENEIC STEM CELL TRANSPLANT
Anjos, A.R.1, Silva, L.1, Kaneno, R.2, Calvi, S.2, Oliveira, J.S.R.1. 1Uni-
versity Federal of Sao Paulo, Sao Paulo, Brazil; 2University State of Sao
Paulo, Botucatu, Sao Paulo, Brazil.
We correlated mRNA and plasmatic TNF-a, IL-2, IFN-g and
IL-10 levels with engraftment, VOD, acute and chronic GvHD in
CML patients underwent to allogeneic BMT. There was no corre-
lation between plasmatic and mRNA cytokines during one year fol-
low-up. Plasmatic TNF-a and IL-10 were not related to acute and
chronic GvHD. In d1 30, patients suffered from acute-GvHD had
lower mRNA IL-2 and IFN-g than those without this involvement
and both were lower than controls. At d 1 360, IFN-g mRNA was
similar, IL-2 mRNA lower and plasmatic IFN-g higher than con-
trols. We showed that IL-2 mRNA is applicable to diagnosis of
chronic GvHD at d 1 180. Lately in the follow-up, we noted as
much as plasmatic TNF-a was decreased, either was IL-10; how-
ever IFN-g and IL-2 were increased. These data ruled out plasmatic
IFN- g and IL-2 as control disease cytokines that prevailed in the
chronic GvHD stable phase after allogeneic BMT.TRANSPLANT NURSING
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PERCEPTION OF KNOWLEDGE OF THE STEM CELL TRANSPLANT (SCT)
PROCESS AND EVALUATION OF SCT TEAM MEMBER FUNCTIONS BY
CAREGIVER(S): A COMPARISON BETWEEN CHILDHOOD MALIGNANT
AND NON-MALIGNANT DISORDER TRANSPLANT FAMILIES
Chadakhtzian, A.L.1, Heidotten, A.1, Yocco, M.1, Barnes, Y.J.1,
Shenoy, S.2. 1St. Louis Children’s Hospital, St. Louis, MO; 2Washington
University School of Medicine, St. Louis, MO.
Background: Allogeneic SCT recipients/families undergo edu-
cational and supportive meetings with a multi-disciplinary team
consisting of nurse coordinator, social worker, child life specialist,
financial specialist, school liaison and child psychologist. Meetings
provide education for SCT procedure. The goal is to promote un-
derstanding of benefits/risks of SCT focusing on helping families
prepare, provide medical, financial, social help and support. Aim:
Quality assessment questionnaire was developed to (1) evaluate
caregiver knowledge of process of SCT (pre-transplant testing, tox-
icities/complications of SCT, post transplant care) for the recipient
diagnosed with malignant/non-malignant disorder and (2) evaluate
perceptions of the role of multidisciplinary team.Methods: Eleven
questionnaires handed to caregivers at discharge from SCT unit to
complete and return anonymously. Questionnaires consisted of 10
questions. Each question was ranked from 1–5 with 5 being the
best. Responses scored 5 were interpreted as excellent, 3–4 consid-
ered good, 1–2 poor level of understanding requiring attention.Re-
sults: 11/11 questionnaires returned/analyzed during 2006–2007
(compliance 100%). Five returned by caregivers of SCT recipients
with malignant disorders and 6 non-malignant disorders. Care-
givers scored understanding of pre-transplant testing, toxicities,
and post transplant care between 3–5. Nurse coordinator, social
worker and child life specialist perceived most important compo-
nents of team. Nurse coordinator and child life specialist received
scores 4–5 from both groups; social worker received scores 4–5
from non-malignant group and 2–5 from malignant group. Finan-
cial specialist, school liaison, and child psychologist received scores
1–5 from both groups. Conclusions: Study suggests no difference
in perceptions of SCT process and education between families of
malignant/non-malignant disorders, and needs to be validated
with larger numbers. Results indicate families are comfortable
with medical information provided regarding SCT and social inter-
actions. The lower scoring of ancillary services suggest an incom-
plete understanding of their role perhaps due to absence of
tangible outcome measures and needs to be emphasized during
pre-transplant education.409
MAD ABOUT STEROIDS: NURSING MANAGEMENT OF THE SCT PATIENT
WITH STEROID-INDUCED PSYCHOSIS
Switzer, M.A. The University of Texas MD Anderson Cancer Center,
Houston, TX.
Prolonged courses of high dose steroids are frequently used to
manage graft vs. host disease (GVHD) following allogeneic stem
cell transplant (SCT). Among the known complications of pro-
longed steroid treatment are mental status changes, effecting up
to 40% of all transplant recipients. Five percent of these alterations
are considered ‘‘severe’’. Symptoms generally present within two
weeks of initiating high-dose therapy. Oftenmanifesting as a persis-
tent, hallucinatory state, these episodes of ‘‘steroid psychosis’’ pres-
ent significant nursing challenges. Patients can be combative,
agitated and are usually noncompliant with treatment regimes. In-
patient SCT nurses often find themselves unprepared to manage
the complex medical and psychosocial needs of patients with acute
psychosis.
Existing literature offers no standard protocols and little guid-
ance to support an evidence-based approach to the nursingmanage-
ment of SCT patients with steroid induced psychosis requiring
long-term hospitalization. A clear need exists to educate nurses co-
ordinating care for this rare but serious side effect of transplant ther-
apy. This poster will bridge the gap and provide nurses insight into
148 Poster Session IIthe development and implementation of successful strategies to
guide the care of patients with steroid induced psychosis.
Successful nursing care plans for inpatients with acute psychosis
must be multi-disciplinary, prioritized to both provide for the pa-
tient’s safety and designed to ensure compliance with prescribed
medications to avoid GVHD exacerbation and infection. When
possible, the team should enlist the support of family members,
who can provide invaluable insight into the patient’s history and
amore thorough assessment of home resources. Timely recognition
of the signs and symptoms of psychosis, coupledwith early interven-
tion, is vital to ensuring successful management and resolution.
Maintaining a consistent caregiver team, employing a 24 hour sitter,
tracking sleep/wake patterns, and encouraging short term/goal di-
rected activities have proven successful. Nurses play a key role in
implementing each of these measures.
A case study will be presented to illustrate nursing interventions
used to manage a patient with steroid-induced psychosis at our
comprehensive cancer center.410
TOTAL GLUCOSE CONTROL (TGC): A GLUCOSE CONTROL PROJECT FOR
STAFF NURSES
Latchford, T.M., Knoepfel, R. Stanford Hospital and Clinics, Stanford,
CA.
Problem: Both the American Diabetes Association and the
American College of Endocrinology have released position state-
ments and standards of medical care regarding glucose control.
The goal is to maintain blood glucose levels of less than 180 mg/
dL in the non intensive care unit (ICU) patient and less than 110
mg/dL at all times in the ICU patient. On the Blood and Marrow
Transplant inpatient unit in 2005 and 2006 the average fingerstick
blood glucose was 209 mg/dL and 200 mg/dL, respectively, well
above the averages of 154 mg/dL and 148 mg/dL of all other inpa-
tients. These high glucoses reflected a lack of compliance with best
practices. The combination of challenges unique to the BMT pop-
ulation include; pain, medical stress, total parental nutrition, and
regular use of glucocorticoids and other immunosuppressants. De-
spite these unique challenges our inpatient unit implemented a total
glucose control (TGC) project in an effort to improve blood glucose
management. Goals: The primary goal of our project was to lower
the inpatient unit’s blood glucose levels by 20%, to an average of
\180 mg/dL. In order to accomplish this, we increased the use of
intravenous insulin infusions and basal-bolus insulin regimens. To
prevent episodes of hyopoglycemia intensive staff education was
provided. Patient education regarding hypoglycemia and blood glu-
cose management was instituted. Implementation: A series of in-
services were developed for BMT physicians and nursing staff.
Pre-project and post-project audits were performed to evaluate
blood glucose levels, length of time until initiation of insulin ther-
apy, number of hypoglycemic episodes, and documentation of pa-
tient education. Results: The TGC project was successful as the
blood glucose average remains less than 180 mg/dL. Conclusion:
To better manage our patients, more education and experience is
needed with the use of the insulin infusion and basal bolus manage-
ment. The insulin infusion is complicated and requires vigilent
management.
The development of guidelines for blood glucose testing and in-
sulin therapy is needed to meet the unique challenges posed by the
BMT patient.
The next step in the TGCproject is to implement these standards
in the outpatient setting.411
RITUXIMAB MONITORING IN HEMATOPOIETIC STEM CELL TRANS-
PLANT: HOW MUCH IS NECESSARY?
Blackburn, R.K., Wood, G., Mick, J.M., Munsell, M.S., Neumann, J.,
Johnston, P. University of Texas MD Anderson Cancer Center, Houston,
TX.Background:Rituximab, an uncongugatedmonoclonal antibody
that reacts with the CD20 molecule present on most malignant B-
cells, is standard treatment for patients with lymphoma. Most ritux-
imab infusions are well tolerated with a mild infusion related symp-
tom complex (fever, chills/rigors) usually occurring within 1 hour
after initiation. Severe infusion related reactions (IRR), such as
bronchospasm and hypotension, occur infrequently; most often
within 2 hours after initiating the first dose. Reactions are caused
by cytokine release associated with high numbers of circulating tu-
mor cells. Incidence of IRRs decreases markedly with subsequent
infusions. At a university based comprehensive cancer center, con-
trolled trials using rituximab for treatment of NHL are underway
in hematopoietic stem cell transplant patients to determine optimal
dosing and scheduling. Patients participating in these trials are
heavily pretreated with rituximab, and are in partial or complete re-
mission before admission for transplant. Based on phase I and II tri-
als, frequent vital sign (VS) monitoring and concurrent
administration of normal saline are recommended. Current organi-
zational clinical practice standards require between 10–16 sets of VS
over 5–6 hours for average rituximab infusions; interfering with pa-
tient comfort and requiring significant nursing time. Purpose: To
determine the frequency and risk of IRRs in patients admitted for
transplant and an optimal vital sign monitoring schedule.Method:
A nurse initiated, IRB-approved, retrospective review of 200 medi-
cal records was conducted. Data analysis is in progress to determine
IRR frequency, identify patients at high risk for reactions, and de-
termine an appropriate VS schedule. Results: Study findings will
be reported.412
WHOSE WHO? A BROWN BAG LUNCH PROGRAM FOR THE STANFORD
BLOOD AND MARROW TRANSPLANT INPATIENT STAFF
Latchford, T.M. Stanford Hospital and Clinics, Stanford, CA.
StanfordUniversity’s Blood andMarrowTransplant (BMT) Pro-
gram performs over 200 transplants a year. Over 150 employees
with diverse backgrounds and responsibilities perform varied func-
tions to faciliate care of BMT recipients and families. The more
than 150 employees are scattered throughout at least 10 different
areas within the university, hospital and clinics. The BMTProgram
staff include: physicians, nurses, advance practice nurses, physician
assistants, nurse coordinators, nursing assistants, unit secretaries,
houskeepers, social workers, physical therapists, dieticians, pharma-
cists, financial coordinators, unrelated donor search coordinator,
administrative staff, stem cell transplant lab technicians, and basic
scientists.
In an effort to help the nurse get to know the diverse role of other
BMT staff within the BMT program, we initiated a brown bag
lunch ‘‘Whose Who Program’’. The Whose Who program asks
a representative from a given area to bring their lunch, sit, and
talk with the nurses over lunch. The goals of the Whose Who pro-
gram are: 1) to share expertise, 2) to allow staff to get to know others
in the BMT program, 3) to develop an understanding of the many
different roles required to care for BMT patients and families. Eat-
ing lunch, getting to know one another, and discussing how each
area contributes to the care of patients in a casual environment
has helped to build a more cohesive team among the many players
that work in our program.413
PRE-STEM CELL TRANSPLANT EDUCATION EFFECT ON PATIENT ANXI-
ETY LEVELS
Scherer, T.M. Christiana Care Health System, Newark, DE.
Stem cell transplantation is a highly technological treatment uti-
lized primarily for hematological malignancies but also used as
treatment for selected solid tumor malignancies as well as benign
disease processes. The concept of impending stem cell transplanta-
tion alone is frightening. The distress caused by the diagnosis and
impending complicated treatment can have a negative impact on
